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The PTTG1-binding factor (PBF/PTTG1IP) has an emerging repertoire of roles, especially in thyroid
biology, and functions as a protooncogene. High PBF expression is independently associated with
poor prognosis and lower disease-specific survival in human thyroid cancer. However, the precise
role of PBF in thyroid tumorigenesis is unclear. Here,wepresent extensive evidencedemonstrating
that PBF is a novel regulator of p53, a tumor suppressor protein with a key role in maintaining
genetic stability, which is infrequently mutated in differentiated thyroid cancer. By coimmuno-
precipitation and proximity-ligation assays, we show that PBF binds specifically to p53 in thyroid
cells and significantly represses transactivation of responsive promoters. Further, we identify that
PBFdecreasesp53 stability byenhancingubiquitination,whichappearsdependenton theE3 ligase
activity of Mdm2. Impaired p53 function was evident in a transgenic mouse model with thyroid-
specific PBF overexpression (transgenic PBF mice), which had significantly increased genetic insta-
bility as indicated by fluorescent inter simple sequence repeat-PCR analysis. Consistent with this,
approximately 40% of all DNA repair genes examined were repressed in transgenic PBF primary
cultures, including geneswith critical roles inmaintaining genomic integrity such asMgmt, Rad51,
and Xrcc3. Our data also revealed that PBF induction resulted in up-regulation of the E2 enzyme
Rad6 in murine thyrocytes and was associated with Rad6 expression in human thyroid tumors.
Overall, this work provides novel insights into the role of the protooncogene PBF as a negative
regulatorofp53 function in thyroid tumorigenesis, inwhichPBF isgenerallyoverexpressedandp53
mutations are rare compared with other tumor types. (Endocrinology 155: 1222–1234, 2014)
Thyroid cancer is the fastest increasing cancer in bothmen and women, with incidence rates rising by 6.6%
per year from 1997 to 2009 (1). Genetic alterations that
govern cancer initiation and progression have been iden-
tified in approximately 75% of cases, which typically in-
volve effectors of the MAPK and phosphatidylinositol
3-kinase pathways (2). Despite effective first-line treat-
ments toablate abnormal thyroid tissue, recurrenceoccurs
in approximately 8–30% of patients (3, 4), and those ge-
netic alterationsdriving tumor recurrence remainobscure.
Recent progress has been made in associating the BRAF
V600E mutation with increased cancer-related mortality
among patients with papillary thyroid cancer (5). How-
ever, the key molecular mechanisms underlying thyroid
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carcinogenesis still need to be better defined to enable de-
velopment of more effective and targeted therapies.
Also known as PTTG1IP, the pituitary tumor trans-
forming gene 1 binding factor (PBF) is a ubiquitously ex-
pressedprotooncogene thatwas first identified through its
ability to bind the human securin PTTG1 (6). Previously,
we showed that sc expression of PBF induced tumors in
athymic nudemice, and that PBF expressionwas higher in
differentiated thyroid carcinomas than in normal thyroid
(7). Separate studies have now identified a role for PBF in
regulating the sodium iodide symporter and themonocar-
boxylate transporter 8 in thyroid cells (8–10). We also
recently demonstrated that thyroid-targeted expression of
PBF resulted in the repression of sodium iodide symporter
function in vivo and induced hyperplastic growth and
macrofollicular thyroid lesions. In contrast to our previ-
ous sc study, however, thyroid tumor induction was ab-
sent in the transgenic mouse model (11). Collectively,
these observations indicate that PBF has an emerging rep-
ertoire of roles, especially in thyroid biology, and likely
functions as a protooncogene. Recently the significance of
PBF as a prognostic biomarker was also demonstrated in
a study of 153 patients with papillary thyroid cancer (12).
High PBF expression was significantly correlated with lo-
coregional recurrence, distantmetastasis at diagnosis, and
disease-specific mortality in patients. The precise role of
PBF in thyroid tumorigenesis, however, has not been
established.
A critical event in the pathogenesis of most, if not all,
human cancers is the disruption of p53 function, a key
regulator in maintaining genetic stability (13) and medi-
ating crucial responses to a range of cellular stresses in-
cluding irradiation-inducedDNAdamage. Formany can-
cers, inactivation of the TP53 gene by somatic mutation
typically occurs late in tumor progression and is often
correlated with cancer aggressiveness and poor survival
(14, 15). For instance, p53mutations have been identified
in 55% of anaplastic thyroid carcinomas, which have a
very poor prognosis due to their aggressive behavior and
resistance to cancer treatments (16). This is in stark con-
trast to well-differentiated thyroid malignancies in which
the prevalence of p53mutations is much lower at approx-
imately 11% (13, 17). There is increasing evidence, how-
ever, that p53 inactivation is also caused by physical in-
teractions of p53 with inhibitory proteins that are
commonly overexpressed in cancer (18, 19). For instance,
the E3 ubiquitin ligase Mdm2/Hdm2 (20, 21) and high
mobility group factor A (17, 22) have both been impli-
cated in the pathogenesis of papillary thyroid carcinomas
due to their ability to bind and inhibit p53 function (23).
It is unclear whether disruption of p53 function by such
proteins also contributes toward the increased sensitivity
of thyroid glands to radiation-induced oncogenesis (24).
Despite the significant progress made in characterizing
proteins that interact with p53, regulation of p53 is highly
complex and involves a myriad of different pathways (25,
26). For instance, PTTG1 has been shown to block bind-
ing of p53 to DNA, thereby inhibiting its ability to induce
apoptosis (27) and to cause p53 stimulation and apoptosis
following overexpression in MCF-7 cells (28). A more
detailed understanding is thus required of the molecular
events that occur following inhibition of p53 function that
help tumor cells escape the tight regulation of key pro-
cesses governing survival and proliferation.
Here, we provide extensive evidence that PBF is a novel
regulator of p53 function in thyroid cells and propose that
PBF’s mechanism of action in thyroid tumorigenesis is via
dysregulation of p53 activity. We have further character-
ized target DNA repair genes downstream of p53 that are
affected by PBF overexpression and have critical roles in
maintaining genomic integrity. This study therefore pro-
vides a novel insight into understanding the role of PBF in
the pathogenesis of thyroid cancer.
Materials and Methods
Cell culture
Primary murine thyrocyte cultures were performed as de-
scribed elsewhere (11). Human thyroid papillary carcinoma
TPC1 and anaplastic thyroid carcinoma SW1736 cells were
kindly provided by Dr Rebecca Schweppe (Division of Endocri-
nology, University of Colorado, Denver, CO), and thyroid pap-
illary carcinoma K1 cells were obtained from the Health Protec-
tionAgencyCultureCollections. The humannon-small-cell lung
cancerH1299cellswerepurchased fromAmericanTypeCulture
Collection (ATCC). All cell lines were kept at low passage num-
ber and cultured in RPMI 1640 (Invitrogen) supplemented with
10% fetal calf serum. Both TPC1 and K1 papillary carcinoma
cells express wild-type (WT) p53 (29, 30), whereas H1299 and
SW1736 cells are both p53 null due to either a homozygous
partial deletion of the TP53 gene or marked down-regulation of
p53mRNA (31). All cell lines usedwere confirmed as genuine by
short tandem repeat analysis (DNADiagnostics Centre) follow-
ing comparison with reported profiles [Supplemental Figure 1
published on The Endocrine Society’s Journals Online web site
at http://endo.endojournals.org; (32)]. Primary thyrocytes were
cultured in modified Ham’s F12 media supplemented with 300
mU/L TSH (Sigma), 100 g/L insulin (Sigma), and 5% fetal calf
serum. Serum was omitted after 72 hours of culture and exper-
iments were performed between 7 and 11 days of culture.
Animals
WTFVB/N and transgenic PBF-Tgmice (11) were bred at the
University of Birmingham, and all experiments were performed
in accordance with UKHomeOffice regulations. Thyroids were
dissected from 6-week-old male PBF-Tg and WT mice for all
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genetic instability, focusedRT2Profiler PCRarray, and real-time
PCR validation experiments. Expression of thyroidal PBF and
Rad6was examined by immunohistochemistry in agedmale and
female PBF-Tg mice with a mean age of 15 months (461  44
days; n 9). Similar trends in protein expression were observed
for male and female PBF-Tg mice compared with age- and sex-
matched WT controls.
Human thyroid samples
Matched tumor and normal tissue specimens were obtained
from 11 patients undergoing surgery for thyroid cancer at the
University Hospital BirminghamNational Health Service Trust,
UK.Normal specimenswere taken from the contralateral lobe at
the time of surgery and were shown to be noncancerous upon
histologic examination. All specimens harvested at the time of
resection were collected with appropriate local ethical commit-
tee approval and informed patient consent.
Transfections
Plasmid DNA and small interfering RNA (siRNA) transfec-
tions were performedwith Fugene6 (Roche) and Lipofectamine-
2000 (Invitrogen) according to manufacturer’s instructions.
Cells were transfected using pooled PBF-specific siRNA (catalog
nos. 4399 and 147350), pooled Rad6-specific siRNA (catalog
nos. 4390824 and 4390825), or negative control siRNA
(AM4635) at a final concentration of 100 nM (Ambion). For
plasmid DNA experiments, cells were transfected with pcDNA3
containing full-length WT PBF cDNA with a hemagglutinin
(HA)-tag, the Rad6 expression vector pCMV6-Ube2a (Cam-
bridge Biosciences), or empty pcDNA3 (Invitrogen) as vector
only (VO) unless otherwise stated, using conditions previously
described (9).
Western blot
Western blot analyses were performed as described previ-
ously (9, 33). Blots were probed with specific antibodies against
PBF (9, 33), 1:200; hemagglutinin (HA;CovanceResearch Prod-
ucts), 1:2000; p53(D0–1) (Santa Cruz Biotechnology), 1:1000,
and Rad6 (Abcam, catalog no. ab31917), 1:1000. Antigen-an-
tibody complexes were detected using the ECL Plus chemilumi-
nescent detection system (AmershamBiosciences). Actin expres-
sion was determined using mouse monoclonal anti--actin
antibody clone AC-15 (Sigma-Aldrich) at 1:10 000. Protein
quantification was performed on cell lysates using the Bradford
assay. To quantify detected bands by densitometry, blots were
scanned into Photoshop (Adobe Systems) keeping all scanning
parameters the same and analyzed using ImageJ software (34).
Binding assays
WT p53 and deletion mutants were cloned into pGEX4T-1
for bacterial expression. L--[35S]methionine-labeled PBF was
expressed in vitro using a TNT T7 Coupled Reticulocyte Lysate
System according to the manufacturer’s guidelines (Promega
Corp.). In vitro glutathione-S-transferase (GST) pull-down as-
says using [35S]PBF andGST-p53proteinswere performedusing
established protocols (35). GST pull-down and coimmunopre-
cipitation (co-IP) assays were performed as described previously
(9). The Duolink in situ proximity ligation assay (PLA) was per-
formed according to manufacturer’s instructions (Olink Biosci-
ence). In our experiments thyroid cells were seeded onto cover-
slips and transfected with expression vectors for p53 (pcDNA3-
p53) andHA-tagged PBF (pcDNA3-PBF) 24 hours later prior to
the PLA assay.
p53 stability assays
In p53 half-life experiments, cells were incubated in 100 M
anisomycin for 2 hours prior to cell lysate extraction using stan-
dard protocols. Nutlin-3 (Sigma-Aldrich) was added to cells at
50 M concentration for 6 hours prior to assessment of p53
stability. In p53 ubiquitination experiments, cells were incu-
bated in20MMG132for2hoursprior to cell lysate extraction.
Quantitative RT-PCR and sequencing
Total RNAwas extracted using the RNeasyMicro Kit (QIA-
GEN) and reverse transcribed using the Reverse Transcription
System (Promega). Expression of specific mRNAs was deter-
mined using 7500 Real-time PCR system (Applied Biosystems).
Gene expression of total RNA extracted from primary thyro-
cytes was analyzed using the DNA damage signaling pathway-
focused RT2 Profiler PCR Array (SABiosciences) according to
manufacturer’s instructions. cDNAwas sequenced to determine
p53 mutational status of human thyroid tumors essentially as
described elsewhere (36). Primer sequences are listed in Supple-
menta1 Figure 8.
Irradiation and genetic instability (GI) assays
DNA damage was induced by Caesium 137 irradiation using
an irradiator IBL 437C type H unit (CIS Bio international). Flu-
orescent inter simple sequence repeat (FISSR)-PCR amplifica-
tions were performed essentially as described previously (37)
using a 5-6-carboxyfluorescein-labeled primer (CA)8RGwith 5
ng of genomic DNA. PCR products were electrophoresed on an
ABI3730 capillary sequencer (Applied Biosystems), and data
were analyzed using Peak Scanner v1.0 software. Five replicate
experiments were performed to verify the reproducibility of the
assay.Thedegreeof genetic instabilitywasdeterminedaccording
to Basik et al (38) to generate the GI index, which represents the
standard measure of GI with ISSR-PCR analysis.
Reporter gene assays
The p53 reporter plasmids phdm2-Luc and p21-Luc have
been described previously (39) and contain fragments of either
the hdm2 or p21 promoter linked to the firefly reporter gene.
H1299 cells were transfected with 400 ng pCIneo-PBF (PBF), 5
ng pcDNA3-p53 (p53), and 150 ng of the indicated p53 reporter
plasmid. The empty plasmid pCIneowithout the PBF cDNAwas
used VO as indicated. The Renilla luciferase control plasmid
pRL (Promega) was used (20 ng per transfection) as an internal
control to normalize firefly luciferase expression. Cellswere har-
vested in Passive Lysis Buffer, and the Dual Luciferase Reporter
Assay System (Promega) was used tomeasure luciferase activity.
Data were normalized to Renilla activity.
Immunohistochemistry and analysis of thyroid
morphology
Thyroid glands were removed from mice using a dissecting
microscope. Tissuewas fixed in 10% formal saline for at least 24
hours prior to being paraffin embedded and cut into 5-m sec-
tions according to standard protocols. Formalin-fixed paraffin-
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embedded sections of mouse thyroid tissue was immunostained
using an avidin-biotin peroxidase technique (Vectastain Elite,
Vector Laboratories). Immunostainingwas performedwith spe-
cific antibodies againstHA (CovanceResearchProducts), 1:200;
and Rad6 (Abcam, catalog no. ab84395), 1:250 using protocols
as described previously (11). For negative controls the primary
antibody was replaced by 10% normal goat serum. Antigen re-
trieval was performed to enhance immunostaining of murine
thyroids by heating tissue sections in boiling 10 mM citrate buf-
fer (pH 6.0) for 10 minutes on a low setting in a domestic mi-
crowave (Panasonic, NN6453; 800W). Hematoxylin and eosin
and immunostained thyroid tissue specimenswere viewed under
a light microscope (Zeiss), and images were captured using Ax-
iovision software (Version 4). A standard 100-mscale bar (Ax-
iovision) was used to convert pixels to micrometers.
Cell survival and apoptosis assays
The cellular viability of TPC1 and SW1736 cultures was
determined using the CellTiter 96 AQueousOne Solution Cell
Proliferation assay (Promega) according to the manufactur-
er’s instructions. Absorbance readings were determined using
a Victor3 plate reader (PerkinElmer) after incubation for 1
hour at 37°C in a humidified chamber containing 5% CO2.
Relative levels of apoptosis were determined by measuring
caspase 3 and 7 enzyme activity using the Caspase Glo 3/7
Apoptosis Kit (Promega), and assays
were performed according to the man-
ufacturer’s instructions.
Statistical analysis
Data are displayed as mean  SE.
Normallydistributeddatawereanalyzed
using a two-tailed Student’s t test, unless
otherwise indicated. P .05was consid-
ered to be statistically significant.
Results
PBF binds to p53
To investigate a role for PBF in
thyroid tumorigenesis, we examined
whether PBF interacts with p53, a
protein critical in suppressing hu-
man cancers. Initial GST pull-down
assays demonstrated that L--[35S]me-
thionine-labeled PBF binds to the
p53 protein (Figure 1A). Successive
deletionmutants ofGST-p53 altered
the stringency of PBF binding. For
instance, PBF did not bind efficiently
to the N terminus region of p53 lo-
cated between amino acids 1–100.
Instead, the strongest binding sites
for PBF appeared to be located
within residues 100–160 and 318–
393 of p53 (Figure 1A). Endogenous
co-IP assays in papillary thyroid can-
cer TPC1 and K1 cells confirmed that p53 specifically
associates with PBF (Figure 1B).
p53 is maintained at low cellular levels but stabilized by
irradiation-inducedDNAdamage.We thereforedetermined
the radiation dose and timing required to yield an optimal
p53 response in both TPC1 and K1 cells (Figure 1C and
Supplemental Figure 2) and examined the subsequent inter-
action between p53 and PBF. Irradiation treatment using
these optimal conditions (ie, 15 Gy, 8 hours) led to an in-
creased quantity of coimmunoprecipitated p53 with PBF in
bothTPC1 (P .05;2.7-fold; Figure 1B) andK1 (P .01;
2.2-fold; Figure 1D) cells compared with controls. PLAs
(40) also demonstrated the presence of red spots of specific
p53 and PBF interaction after transient transfection in both
TPC1 (Figure 1E and Supplemental Figure 3, A and B) and
K1 cells (Supplemental Figure 3C).
PBF increases turnover and ubiquitination of p53
p53 is an intrinsically unstable protein that is subject to
rapid degradation and is rarely mutated in differentiated
Figure 1. Interaction between PBF and p53. A, Binding of [35S]PBF to GST-p53 (1–393) and GST-
p53 deletion mutants as indicated vs a GST-only control. Schematic of domain structure of p53 and
deletion mutants showing a transcriptional activation domain (TAD), proline rich domain (PRO), DNA-
binding domain (DBD), tetramerization domain (TET), and C-terminal (C-TERM). B, Co-IP of p53 with
PBF in TPC1 cells either untreated (IR) or irradiated with 15 Gy for 8h (IR). Nab, no antibody
control. Graph shows quantified levels of p53 SE from 3 independent experiments. C, Western blot
analysis of p53 in TPC1 cells irradiated with 0- to 40-Gy dose as indicated for 8 hours (upper), or
irradiated () with 15-Gy dose and p53 protein levels monitored at 0, 2, 8, or 24 hours after
treatment compared with untreated () controls (lower). D, Co-IP of p53 with PBF in K1 cells either
untreated (IR) or irradiated with 15 Gy for 8 hours (IR). Nab, no antibody control. Graph shows
quantified levels of p53 SE from 3 independent experiments. E, PLA assay to demonstrate specific
PBF and p53 interaction (red spots) in TPC1 cells transiently transfected for 24 hours with plasmid
expression vectors for p53 and HA-tagged PBF. Scale bars, 10 m. *, P .05; **, P .01.
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thyroid cancer. To further investigate the relationship
between PBF and p53 in thyroid cells, we examined
whether interaction with PBF resulted in altered p53
stability. Half-life studies using anisomycin to block de
novo protein synthesis showed that overexpression of
PBF significantly increased turnover of p53 protein in
TPC1 (P  .01; Figure 2, A and B) and K1 (P  .05;
Figure 2C) cells compared with VO controls after 120
minutes. Importantly, control experiments showed that
p53 mRNA levels did not change significantly in TPC1
cells following overexpression of PBF compared with
VO (Figure 2D). To determine whether the reverse re-
lationship held true, we depleted PBF (Figure 2E) and
observed greater p53 stability, with more than 4-fold
higher p53 levels (P  .05) in K1 cells compared with
negative controls after 120 minutes, and no significant
turnover over the time course (Figure 2, F and G). In-
creased p53 stability was also evident in PBF-depleted
TPC1 cells compared with controls at 120minutes after
anisomycin treatment (data not shown).
Given that modulation of PBF expression was associ-
ated with altered p53 stability, we examined p53 ubiq-
uitination in cells treated with the proteasome inhibitor
MG132. A significant increase in the level of high molec-
ularweight p53 conjugateswas present in PBF-transfected
TPC1 cells treatedwithMG132 (Figure 3A),which is con-
sistent with the accumulation of ubiquitinated p53.
Mdm2has been identified as themajor E3 ubiquitin ligase
of p53, binding and targeting it for proteasome-mediated
degradation. We therefore investigated whether the in-
creased turnover of p53 by PBF in thyroid cells was de-
pendent on the E3 ligase activity of Mdm2. The addition
of the inhibitor nutlin-3 to block binding ofMdm2 to p53
led to a significant increase in p53 stability in VO- (Figure
Figure 2. PBF decreases p53 intracellular stability Representative Western blot analysis of p53 in (A) TPC1 and (C) K1 cells transfected with either
VO or PBF and then lysed at indicated times after treatment with 100 M anisomycin. Detection of HA epitope was used to monitor transfection.
Mean p53 protein levels relative to -actin in TPC1 cells are shown in panel B from 3 independent experiments. D, Relative mRNA levels of p53 in
TPC1 cells transfected with either VO or PBF. E, Relative mRNA levels of PBF in K1 cells transfected with either PBF-specific or control siRNA for 72
hours at a concentration of 100 nM. F, Representative Western blot analysis of p53 in K1 cells transfected with either PBF-specific or control siRNA
and then lysed at indicated times after treatment with 100 M anisomycin. G, Quantification of p53 protein levels relative to -actin from p53
half-life experiments in K1 cells transfected with either PBF-specific or control siRNA. Data presented as mean p53 levels  SE from 3 independent
experiments. *, P  .05; ***, P  .001; NS, not significant (P 	 .05).
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3B) and PBF-transfected TPC1 cells (Figure 3C). Quanti-
fication of p53 protein showed that equivalent levels of
p53 were present in VO- and PBF-transfected TPC1 cells
at both 60 and 90 minutes after treatment with nutlin-3
(P  NS; n  3; Figure 3D). This was in contrast to a
significant decrease in p53 stability in the absence of nut-
lin-3 in PBF-transfected cells at the same time points (P
.05; Figure 3D). Therefore, the ability of PBF to diminish
p53 stability in thyroid cells appears to be Mdm2 depen-
dent with no evidence of any additive or synergistic
interactions.
PBF inhibits p53 activity and alters sensitivity of
thyroid cells to irradiation
Following our observations that PBF binds and regu-
lates p53 stability, we next analyzed whether PBF altered
the transactivation activity of p53 in transient reporter
assays in H1299 cells, which are p53 null. When coex-
pressed, PBF significantly repressed p53-mediated hdm2
promoter activity by approximately 60% (P .001; Fig-
ure 4A), aswell as p21 promoter activity (25%;P .01;
Figure 4B).We next depleted PBF (Figure 4, C andD) and
observed a significant increase in themRNAexpression of
p21, a well-characterized p53-responsive gene, in both
TPC1 (2.4-fold; P  .05) and K1 (3.7-fold; P  .001)
papillary thyroid cells (Figure 4E). Examination of apo-
ptotic markers also indicated a corresponding increase in
caspase-3/7 activity in PBF-depleted TPC1 (2.4-fold; P
.05; Figure 4F) and K1 cells (1.45-fold; P  .05; Supple-
mental Figure 4A).
To further investigate the physiological relevance of
our finding that PBF alters p53 stability and activity, we
next examined the influence of manipulating PBF expres-
sion on apoptosis and cell survival in response to irradi-
ation. Interestingly, depletion of PBF in TPC1 cells ap-
peared to enhance their sensitivity to irradiation with a
greater fold-change in caspase-3/7 activity (4.35-fold;P
.01; Figure 4F) and a significant decrease in cell viability
(P  .05; Supplemental Figure 4B). Furthermore, in the
absence of PBF, TPC1 cell survival was reduced by ap-
proximately 20% in response to irradiation (Figure 4G),
whereas cells transfected with PBF demonstrated no de-
crease in cell survival (P  .001). Importantly, there was
no difference in the cell viability of irradiated p53-null
SW1736 thyroid cells transfected with either VO or PBF
(P  NS; Supplemental Figure 4C), suggesting that the
effects of PBF on cell survival may be p53 dependent. To-
gether these results support the notion that the functional
consequences of PBF dysregulation are via regulation of
p53 activity.
PBF dysregulates DNA repair genes and promotes
genetic instability
We next examined whether PBF depletion in thyroid
cell lines also caused dysregulation of other p53-respon-
sive genes. Figure 5A shows that significant mRNA
changes were indeed observed in PBF-depleted TPC1 and
K1 cells for a number of other genes includingDNA repair
genes such as Rad50, Rad51, Brca1, and Brca2. To un-
derstand the effect of PBF dysregulation in a more phys-
iologically relevant thyroid-disease model, we next exam-
ined the transcriptional profile of a panel of 83 p53-
regulated genes in murine primary PBF-Tg thyrocytes
compared with WT thyrocytes (Figure 5B). A total of 27
Figure 3. Effect of PBF on p53 ubiquitination. A, Detection of high
molecular weight (mwt) p53 conjugates by Western blot analysis in
TPC1 cells transfected with either VO or PBF and then treated with
10 M MG132. B and C, Western blot analysis of p53 in TPC1 cells
transfected with either VO or PBF and then incubated with 50 M
nutlin-3 prior to 100 M anisomycin treatment. Dimethylsulfoxide
(DMSO) was used as vehicle. D, Mean p53 protein levels relative to
-actin quantified from 3 independent experiments are shown.
Data presented as mean  SE. *, P  .05; NS, not significant (P 	
.05).
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genes showed significant expression changes (P  .05),
suggesting wide-ranging dysregulation in response to
raised PBF. Of these, 12 genes showed altered mRNA ex-
pressionmore than 1.5-fold (Figure 5C), including several
genes known tomaintain genomic integrity, such asXrcc3
(0.42 0.09; P .003), Fancg (0.58 0.1; P .02), and
Rad51c (0.65  0.09; P  .02).
Primary thyrocyte cultures from PBF-Tg mice were
next irradiated in order to identify additional p53-respon-
sive candidate genes that might be disrupted by elevated
endogenous PBF in nontransformed cells. A total of 10
genes, including Rad51, Chek1, and Rad6, showed sig-
nificant changes (	1.5-fold;P .05) in theirmRNAlevels
following irradiation of PBF-Tg thyrocytes compared
withWT (Supplemental Figure 5). Normalization of data
to adjust for PBF effects on gene expression identified 8
genes most significantly dysregulated by elevated PBF fol-
lowing irradiation (Figure 5D). For example, irradiation-
induced expression of the p53-responsive genes Mgmt
(2.0  0.03-fold) and Polk (1.7  0.08-fold) was signif-
icantly suppressed in PBF-Tg thyrocytes compared with
WT (P  .0007 and P  .05 respectively; Figure 5D). In
contrast, the degree of irradiation-induced inhibition for
several genes, including Ung (P  .02) Fancg (P  .05),
andMbd4 (P .04), was abrogated in PBF-Tg thyrocytes
following irradiation. Validation experiments using indi-
vidual qPCR assays also confirmed significant differences
in expressionofMgmt (P .009),Rad51 (P .0002), and
Figure 4. PBF inhibits p53 transcriptional activity. H1299 cells were transfected with p53 luciferase reporter plasmids for either (A) hdm2 (phdm2-
Luc) or (B) p21 (p21-Luc), as well as p53 and PBF expression vectors, or VO as indicated. Luciferase activity was measured 24 hours after
transfection. C and D, TPC1 cells were transfected with either PBF-specific or control siRNA at a final concentration of 100 nM. PBF expression was
assessed by Western blotting and quantitative RT-PCR analysis as shown. E, Relative mRNA levels of p21 mRNA in TPC1 and K1 cells transfected
with either PBF-specific or control siRNA for 48 hours at a concentration of 100 nM. F, Analysis of caspase-3/7 activity in TPC1 cells transfected
with either PBF-specific or control siRNA for 48 hours and then irradiated with a 15 Gy dose (IR) or untreated (IR). Normalized mean caspase-3/
7 values  SE are shown from 4 independent experiments. For each experiment caspase-3/7 activity was determined from n  5 per condition at
24 hours postirradiation. G, TPC1 cells were transfected with either VO or PBF for 24 hours and either untreated (IR) or irradiated (IR) with a
15-Gy dose. Cells were then replated and viability measured after 24 hours. Data presented as mean  SE from 4 independent experiments. *,
P  .05; **, P  .01; ***, P  .001; NS, not significant (P 	 .05).
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Chek1 (P  .002) in PBF-Tg thyrocytes after irradiation
(Supplemental Figure 6). Furthermore, irradiation did not
cause any transcriptional changes in either TP53 (Figure
5D) or PBF (Figure 5E).
To investigate whether the ability of PBF to abrogate
p53 activity and downstream DNA repair genes might
also influence genetic stability in vivo, we next used flu-
orescent inter simple sequence repeat (FISSR) PCR (37) to
analyze genetic instability in thyroid glands dissected from
PBF-Tg and WT mice. In comparison with age- and sex-
matched WT mice (arbitrarily assigned a GI of 0%), the
thyroids of 6-week old PBF-Tg mice demonstrated signif-
Figure 5. PBF dysregulates DNA repair gene expression and promotes genetic instability. A, Relative mRNA expression of indicated genes in TPC1
and K1 cells transfected with either PBF-specific or control siRNA for 48 hours at a concentration of 100 nM. B, Pie chart summarizes expression
changes of DNA repair genes between PBF-Tg and WT thyrocytes (n  3 arrays). C, Relative mRNA expression levels of 12 genes ( 1.5-fold; P 
.05) in PBF-Tg thyrocytes compared with WT. D, Relative fold changes in mRNA expression of indicated 9 genes following irradiation of either WT
or PBF-Tg thyrocytes compared with nonirradiated controls as indicated. Data presented as mean  SE from at least 3 independent experiments. E,
Relative mRNA levels of PBF in WT primary thyrocytes either untreated (IR) or irradiated with a 15-Gy dose (IR). F, Quantification of GI in
murine PBF-Tg thyrocytes compared with WT (n  5). Data presented as mean GI index  SE. A representative FISSR-PCR trace amplified from
PBF-Tg thyrocyte gDNA is shown plotted against a LIZ1200 size standard. *, P  .05; **, P  .01; ***, P  .001; NS, not significant (P 	 .05).
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icantlydisruptedgenomes,withameanGI indexof19.8
1.8% (P .001; Figure 5F). Altogether, these results iden-
tify a panel of p53-responsive DNA repair genes that are
dysregulated by elevated PBF levels in primary thyrocytes
and are associated with genetic changes underlying the
increased GI index observed in PBF-Tg thyroids. Among
these, the expression of Rad6, also known as the ubiqui-
tin-conjugating enzyme E2A (Ube2a), was the sole gene
up-regulated more than 1.5-fold (P  .008) in PBF-Tg
thyrocytes.
Functional interaction between p53 and Rad6 in
thyroid cells
Recently, Rad6 has been shown to form a ternary com-
plex with Mdm2 and p53 that contributes to p53 degra-
dation inHeLa cells (41).We therefore examinedwhether
Rad6 also binds to p53 in thyroid cells. Exogenous co-IP
assays confirmed that Rad6 specifically binds to p53 in
TPC1 cells (Figure 6A). Importantly, overexpression of
Rad6 in both TPC1 (Figure 6A) and K1 (Figure 6B) thy-
roid cells led to a significant decrease in p53 protein levels.
In addition, depletion of Rad6 in K1 cells increased p53
protein levels (Figure 6B).
Having established that a functional interaction exists
between Rad6 and p53 in thyroid cells, we next examined
the relationship between PBF and Rad6 in thyroid disease
models in vivo. For these experiments we used thyroid
glands dissected from PBF-Tg mice, which have an en-
larged and hyperplastic phenotype [Figure 6C; (11)]. Im-
munostaining revealed elevated Rad6 expression in thy-
roids from 15-month-old PBF-Tg mice compared with
Figure 6. Association of Rad6 and PBF in vivo. A, Western blot analysis (upper) of co-IP of Rad6 with p53 in TPC1 cells transfected for 24 hours
with either VO () or pCMV6-Ube2a (). ISO, isotype control antibody. Nab, no antibody control. Western blot analysis of Rad6 (middle) and p53
(lower) in cell lysates from transfected TPC1 cells are also shown. B, Western blot analysis of Rad6 and p53 following either overexpression (upper)
or depletion (lower) of Rad6 in K1 cells. Control lanes are indicated. C, Representative enlarged thyroids dissected from aged PBF-Tg mice
compared with WT. Thyroids were typically approximately 3- to 4-fold heavier in PBF-Tg mice. D and E, Representative images of Rad6 staining in
normal regions (D) and hyperplastic lesions (E) in WT (n  6) and PBF-Tg (n  9) thyroids are shown. Arrows highlight elevated nuclear expression
of Rad6 (E). F, Correlation of PBF and Rad6 mRNA expression in human thyroid tumors (n  11). Statistics analyzed using Spearman rank
correlation. G, Graph shows quantification of Rad6 mRNA expression in thyroid tumors relative to normal thyroid. Scale bars, 100 m. Data
presented as mean  SE. **, P  .01.
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age-matched WT thyroids (Figure 6D and Supplemental
Figure 7A). Previous studies have indicated weak cyto-
plasmic Rad6 staining in normal cells compared with in-
tense nuclear reactivity in invasive tumor cells (42). Here,
Rad6 expressionwasmost prominent in nuclear compart-
ments of follicular epithelial cells in PBF-Tg thyroids,
whereas WT cells displayed mostly diffuse cytoplasmic
staining (Figure 6D). Importantly, the greatest abundance
ofRad6nuclear immunoreactivitywas detected in distinct
hyperplastic lesions (Figure 6E), which also colocalized
with highest expression of the HA-tagged PBF transgene
(Supplemental Figure 7B). In further studies, evaluation of
matchednormal and tumorhuman thyroid specimens also
revealed a significant positive correlation between PBF
and Rad6 mRNA expression (Figure 6F; P  .001; rs 
0.9),with a significant 1.60.2-fold induction (P .008)
in Rad6 mRNA levels in thyroid tumors compared with
normal tissue (Figure 6G). cDNA sequence analysis
showed all human thyroid tumors had WT p53 (Supple-
mental Figure 8). Taken together, these results suggest a
significant association between elevated PBF and Rad6
expression in thyroid diseasewithWTp53 status. The low
mutation rate of the p53 gene in differentiated thyroid
cancer may therefore belie functional inactivation of the
protein by PBF, which is up-regulated in differentiated
thyroid cancer, increases p53 turnover, and induces the
expression of Rad6, a known regulator of p53 activity.
Discussion
The functional disruption of p53 activity has a critical role
inpromoting tumorigenesis inmanydifferent typesof can-
cer (15). However, the mechanisms governing p53 inac-
tivation remain to be fully defined, especially in tumors
such as in differentiated thyroid cancer that have a lower
incidence of p53mutations (16, 17). Our current findings
now indicate that the role of the relatively uncharacterized
gene PBF in cell transformation most likely reflects its in-
teraction with p53, thus providing a novel insight into the
ability of PBF to promote endocrine tumorigenesis.
There has been relatively little reported concerning a
possible role for PBF in tumorigenesis, despite identifica-
tionof thePBF gene in1998 (43).Wepreviously described
PBF overexpression in thyroid (7), pituitary (44), and
breast cancers (33). Subsequent functional studies high-
lighted that PBF was a transforming gene in vitro and
induced sc high-grademalignant tumor formation in athy-
mic nude mice (7). However, the underlying role for PBF
in tumorigenic growth in vivo remains unclear, especially
because transgenic mice with thyroid-specific PBF expres-
sion did not develop thyroid cancer (11).
To therefore gain further insight into the role of PBF in
tumorigenesis we investigated the ability of PBF to bind
p53 byGSTpull-down, co-IP and PLAs.Our data showed
that PBF bound specifically to p53 in vitro and the relative
level of p53-PBF coimmunoprecipitates in thyroid cells
was enhanced by -irradiation. These results most likely
reflect the greater abundance of stabilized p53 protein
following irradiation because p53 protein levels were, as
expected, increased in irradiated TPC1 and K1 cells, in
contrast to minimal changes in PBF protein (data not
shown).
It is well documented that proteins such as Mdm2 and
USP10 (45) can bind p53 and target it for degradation or
promote its intracellular stability.This ledus to investigate
whether the ability of PBF to interact with p53 might also
alter its turnover. Our results indicated that PBF has a role
in diminishing p53 stability because PBF overexpression
significantly increased p53 turnover in thyroid cancer
cells. Further evidencewas providedbydepleting PBFpro-
tein,which increased p53 stability, aswell as the enhanced
ubiquitination of p53 in PBF-overexpressing cells as evi-
denced by the accumulation of highmolecular weight p53
conjugates. These findingsmight infer a direct role for PBF
inubiquitinatingp53,but the aminoacid sequence forPBF
does not contain a typical ubiquitin-conjugating (UBC)
(46) or E3 ligase domain (47). Additionally, p53 degra-
dation was blocked by the inhibitor nutlin-3 with no syn-
ergistic or additive effects in the presence of elevated PBF,
thereby indicating that the effects of PBF on p53 ubiquiti-
nation may involve Mdm2.
GST pull-down assays using deletion mutants of p53
highlighted 2 possible regions that might be involved in
binding PBF. One of these, located between residues 318
and 393, contains the key lysines ubiquitinated byMdm2
(48), which binds the N-terminal domain of Mdm2 (49).
We therefore envisage that PBF may modulate the asso-
ciation of p53/Mdm2 with interacting proteins such as
histone deacetylases (50), P300/CBP-associated factor
(51), p300/CREB-binding protein (51), and Tip60 (52)
that are known to alter p53 acetylation andubiquitination
status. The regulation ofMdm2 is, however, a focal point
of numerous regulatory pathways for p53, including both
transcription and nontranscriptional targets of p53 (26).
For example, the transcription factor YY1 enhances p53
degradation by increasing the binding of Mdm2 to p53
(53). Future investigations will thus need to focus on the
precise functional relationship between PBF and p53/
Mdm2-interacting partners, as well as the interaction be-
tween Mdm2 and p53 itself.
Previous studies have identified that PBF can interact
with the protooncogene PTTG1 to facilitate its transloca-
tion into the nucleus (6). Hence, it is possible that an al-
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ternative mechanism exists such that PBF might augment
PTTG1’s nuclear function as the human securin, inhibit-
ing mitosis and generating intrachromosomal breaks, as
well as increasing the interactionbetweenPTTG1andp53
(27, 28, 54). Indeed, we have also reported that PTTG1
induces genetic instability in colorectal cells, and that
PTTG1 expression correlates with genetic instability in
vivo (37). Against this, our current data reveal the novel
finding that PBF and p53 bind specifically, particularly in
the presence of DNA damage, and that p53 stability was
significantly altered by PBF. Furthermore, preliminary
co-IP experiments showed that the PBF-p53 interaction
was not significantly altered in PTTG1-depleted TPC1
cells (data not shown). These results therefore imply an
independence of action for PBF.
Disruption of p53 by interaction with other proteins
typically results in loss of activity of p53-responsive genes.
Our data of reduced transactivation of Hdm2 and p21
promoters in p53-null H1299 cells transfected with PBF
and p53 are therefore in keeping with those in the litera-
ture. Indeed, the magnitude of this inhibition was broadly
equivalent to proteins such as Polo-like kinase 1 (Plk1)
that also physically interact with p53 (55). Importantly,
we showed that depletion of PBF in thyroid cells also in-
creasedexpressionof thep53-responsivegenep21, further
emphasizing the role of PBF as a negative regulator of p53
activity. Our group recently reported the generation of a
PBF-Tg mouse with targeted human PBF overexpression
in the thyroid gland (11). In this study, we were able to
show dysregulated expression of approximately 40% of
all DNA repair genes examined (32 of 83) in PBF-Tg pri-
mary thyrocytes. It will be important to determine the
relative contribution of p53-independent pathways, if
any, to the ability of PBF to disrupt expression of these
genes. However, expression of many of the genes identi-
fied, such as Mgmt, are known to be modulated by ion-
izing radiation in a classicalWTp53gene-dependentman-
ner (56); thus, the ability of PBF to abrogate these genes
provides an invaluable startingpoint for defining a role for
PBF in regulating p53 pathways.
Higher levels of mRNA encoding the E2 enzyme Rad6
in PBF-Tg thyrocytes highlighted a potential route via
which PBF might disrupt p53 stability. Subsequent exam-
ination of PBF-Tg thyroid glands revealed an increased
abundance of nuclear Rad6 protein, a feature of invasive
tumor cells (42), which colocalized with high PBF expres-
sion, especially at hyperplastic lesions. Recently it was
shown that Rad6 plays a critical role in regulating p53
protein levels by forming a ternary complex with Mdm2
and p53 that contributes to p53 degradation inHeLa cells
(41). Our results therefore indicate that PBF might also
up-regulate Rad6 expression in order to decrease p53 sta-
bility. The precisemechanism bywhich PBF induces Rad6
is the subject of further work, although p53 response el-
ements are located in the Rad6 promoter (57). However,
we were able to confirm for the first time in thyroid cells
that Rad6 coimmunoprecipitates with p53 and overex-
pression ofRad6 decreases p53 protein levels. In addition,
a significant correlation was evident between PBF and
Rad6 mRNA expression in human thyroid cancer speci-
mens, further emphasizing the interaction between these 2
genes in thyroid disease.
Genomic instability is an evolving hallmark of cancer
but themolecular basis is poorly defined (58). In our study
elevated genetic instability was present in PBF-Tg mouse
thyroids and associatedwith extensive repression ofDNA
repair genes. Of particular importance, the disruption of
several genes highlighted in this study, including the
Rad51 family (ie, Rad51, Xrcc3, Xrcc2, and Rad51c),
have been associated with an increased risk of thyroid
cancer (59). Furthermore, inactivation ofMgmt has been
suggested to cause somatic mutations in RAS (60), a gene
commonly mutated in thyroid neoplasms. Our results in
this study would therefore suggest a novel mechanism for
tumorigenesis such that PBF overexpression may disrupt
DNArepair enzymeswith critical roles in thepathogenesis
of cancer, as well as contributing to the overall genetic
instability typically associated with tumor progression
(61).
We previously showed that thyroid cancers displaying
recurrence demonstrate particularly high PBF levels (7).
Similarly, a recent study showed that high PBF expression
was significantly correlated with locoregional recurrence
and distant metastases at diagnosis in patients with pap-
illary thyroid cancer (12). These findings support a larger-
scale clinical evaluation to determinewhether PBF expres-
sion in thyroid cancer correlates with genetic instability
and somatic mutations typically associated with aggres-
sive disease and increased mortality such as BRAF V600E
(5).
In summary, we describe PBF as a novel interacting
partner of p53, which alters p53 stability and transacti-
vation capabilities. In defining a role for PBF, we demon-
strate that it interferes with DNA repair pathways and
induces genetic instability in thyroid cells in vivo. This
work therefore provides an important insight into the role
of the protooncogene PBF as a negative regulator of p53
in thyroid tumorigenesis, where PBF is generally overex-
pressed and p53 mutations relatively rare. It will also be
important to determine whether high thyroidal PBF is a
risk factor for irradiation-associated tumors, especially in
individuals with multinodular goiters in which elevated
PBF expression has been described (11). Together these
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findings further emphasize that PBF has an increasingly
important role in the etiology of thyroid disease.
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